AP NEWS

Bladder Cancer Epidemiology in Europe 2018: Patient Flow, Prevalence and Diagnosed & Treated Patient Analysis to 2026 - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Europe Bladder Cancer Epidemiology and Patient Flow Analysis - 2018” report has been added to ResearchAndMarkets.com’s offering.

The research provides insights into Bladder Cancer epidemiology, Bladder Cancer diagnosed patients, and Bladder Cancer treatment rate for EU5 countries. The research measures key indicators including prevalence of Bladder Cancer derived from epidemiological analysis, patients diagnosed with Bladder Cancer, and patients treated with a drug therapy.

The research study helps executives estimate Bladder Cancer market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The research provides estimates and forecasts of Bladder Cancer prevalence, Bladder Cancer diagnosis rate, and Bladder Cancer treatment rate for the period 2017-2026. The information is presented by EU5 countries including Germany, France, Spain, Italy, and UK.

Key Features

Bladder Cancer Patient Flow Bladder Cancer Prevalence Bladder Cancer Diagnosed Patients Bladder Cancer Treated Patients

Key Topics Covered

1. Bladder Cancer: Disease Definition

2. Bladder Cancer Patient Flow in Europe

2A. Bladder Cancer Prevalence in Europe

2B. Bladder Cancer Diagnosed Patients in Europe

2C. Bladder Cancer Treated Patients in Europe

3. Bladder Cancer Patient Flow in Germany

3A. Bladder Cancer Prevalence in Germany

3B. Bladder Cancer Diagnosed Patients in Germany

3C. Bladder Cancer Treated Patients in Germany

4. Bladder Cancer Patient Flow in France

4A. Bladder Cancer Prevalence in France

4B. Bladder Cancer Diagnosed Patients in France

4C. Bladder Cancer Treated Patients in France

5. Bladder Cancer Patient Flow in Spain

5A. Bladder Cancer Prevalence in Spain

5B. Bladder Cancer Diagnosed Patients in Spain

5C. Bladder Cancer Treated Patients in Spain

6. Bladder Cancer Patient Flow in Italy

6A. Bladder Cancer Prevalence in Italy

6B. Bladder Cancer Diagnosed Patients in Italy

6C. Bladder Cancer Treated Patients in Italy

7. Bladder Cancer Patient Flow in UK

7A. Bladder Cancer Prevalence in UK

7B. Bladder Cancer Diagnosed Patients in UK

7C. Bladder Cancer Treated Patients in UK

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/research/dzb5d9/bladder_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611006233/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Bladder Cancer Drugs

KEYWORD: EUROPE

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 05:12 PM/DISC: 06/11/2018 05:12 PM

http://www.businesswire.com/news/home/20180611006233/en

AP RADIO
Update hourly